Advanced

Serum IL-15 in patients with early systemic sclerosis: a potential novel marker of lung disease

Wuttge, Dirk LU ; Wildt, Marie LU ; Geborek, Pierre LU ; Wollheim, Frank LU ; Scheja, Agneta LU and Åkesson, Anita LU (2007) In Arthritis Research and Therapy 9(5).
Abstract
ABSTRACT: The pathogenesis of systemic sclerosis (SSc) is characterized by autoimmunity, vasculopathy and fibrosis. IL-15 is a pleiotropic cytokine that has impact on immune, vascular and connective tissue cells. We therefore investigated IL-15 in the circulation of patients with early SSc and explored possible associations of serum IL-15 with vasculopathy and fibrosis. Serum levels of IL-15 were analysed in 63 consecutive patients with SSc of disease duration less than 4 years and without disease-modifying treatment. Thirty-three age-matched healthy control individuals were enrolled. Serum IL-15 levels were increased in the sera of SSc patients compared with that of healthy control individuals (P < 0.01). Serum IL-15 levels correlated... (More)
ABSTRACT: The pathogenesis of systemic sclerosis (SSc) is characterized by autoimmunity, vasculopathy and fibrosis. IL-15 is a pleiotropic cytokine that has impact on immune, vascular and connective tissue cells. We therefore investigated IL-15 in the circulation of patients with early SSc and explored possible associations of serum IL-15 with vasculopathy and fibrosis. Serum levels of IL-15 were analysed in 63 consecutive patients with SSc of disease duration less than 4 years and without disease-modifying treatment. Thirty-three age-matched healthy control individuals were enrolled. Serum IL-15 levels were increased in the sera of SSc patients compared with that of healthy control individuals (P < 0.01). Serum IL-15 levels correlated with impaired lung function, assessed both by the vital capacity (P < 0.05) and by the carbon monoxide diffusion capacity (P < 0.05). The association between IL-15 and the vital capacity remained after multiple linear regression analysis. Patients with intermediate serum IL-15 levels had a higher prevalence of increased systolic pulmonary pressure compared with patients with either low or high serum IL-15 levels (P < 0.05). Moreover, increased serum IL-15 levels were associated with a reduced nailfold capillary density in multivariable logistic regression analysis (P < 0.01). Serum IL-15 levels also correlated inversely with the systolic blood pressure (P < 0.01). We conclude that IL-15 is associated with fibrotic as well as vascular lung disease and vasculopathy in early SSc. IL-15 may contribute to the pathogenesis of SSc. IL-15 could also be a candidate biomarker for pulmonary involvement and a target for therapy in SSc. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Arthritis Research and Therapy
volume
9
issue
5
publisher
BioMed Central
external identifiers
  • pmid:17784951
  • wos:000252468400008
  • scopus:35748952537
ISSN
1478-6362
DOI
10.1186/ar2284
language
English
LU publication?
yes
id
1ba0553b-ee76-4637-9c43-84c4f42ab6fb (old id 1141053)
date added to LUP
2008-08-13 14:19:26
date last changed
2017-08-13 04:35:45
@article{1ba0553b-ee76-4637-9c43-84c4f42ab6fb,
  abstract     = {ABSTRACT: The pathogenesis of systemic sclerosis (SSc) is characterized by autoimmunity, vasculopathy and fibrosis. IL-15 is a pleiotropic cytokine that has impact on immune, vascular and connective tissue cells. We therefore investigated IL-15 in the circulation of patients with early SSc and explored possible associations of serum IL-15 with vasculopathy and fibrosis. Serum levels of IL-15 were analysed in 63 consecutive patients with SSc of disease duration less than 4 years and without disease-modifying treatment. Thirty-three age-matched healthy control individuals were enrolled. Serum IL-15 levels were increased in the sera of SSc patients compared with that of healthy control individuals (P &lt; 0.01). Serum IL-15 levels correlated with impaired lung function, assessed both by the vital capacity (P &lt; 0.05) and by the carbon monoxide diffusion capacity (P &lt; 0.05). The association between IL-15 and the vital capacity remained after multiple linear regression analysis. Patients with intermediate serum IL-15 levels had a higher prevalence of increased systolic pulmonary pressure compared with patients with either low or high serum IL-15 levels (P &lt; 0.05). Moreover, increased serum IL-15 levels were associated with a reduced nailfold capillary density in multivariable logistic regression analysis (P &lt; 0.01). Serum IL-15 levels also correlated inversely with the systolic blood pressure (P &lt; 0.01). We conclude that IL-15 is associated with fibrotic as well as vascular lung disease and vasculopathy in early SSc. IL-15 may contribute to the pathogenesis of SSc. IL-15 could also be a candidate biomarker for pulmonary involvement and a target for therapy in SSc.},
  articleno    = {85},
  author       = {Wuttge, Dirk and Wildt, Marie and Geborek, Pierre and Wollheim, Frank and Scheja, Agneta and Åkesson, Anita},
  issn         = {1478-6362},
  language     = {eng},
  number       = {5},
  publisher    = {BioMed Central},
  series       = {Arthritis Research and Therapy},
  title        = {Serum IL-15 in patients with early systemic sclerosis: a potential novel marker of lung disease},
  url          = {http://dx.doi.org/10.1186/ar2284},
  volume       = {9},
  year         = {2007},
}